What is the role of icosapent ethyl (EPA) in lipid management?

Enhance your knowledge of antihyperlipidemics and lipid management. Study with multiple choice questions and detailed explanations. Ace your test!

Multiple Choice

What is the role of icosapent ethyl (EPA) in lipid management?

The main idea is that icosapent ethyl provides cardiovascular benefit when added to statin therapy for adults with elevated triglycerides, at a dose of 2 g twice daily. This comes from trials showing that high-dose EPA reduces major adverse cardiovascular events in people with triglycerides ≥150 mg/dL on statins. The effect is thought to come from lowering triglycerides and anti-inflammatory actions that help stabilize plaque, rather than dramatically changing LDL or HDL. It is not a cholesterol absorption inhibitor (that’s ezetimibe), it does not reliably raise HDL-C by a fixed amount, and it does not produce a 50% reduction in LDL-C—LDL changes are not the driver of the observed CV risk reduction.

The main idea is that icosapent ethyl provides cardiovascular benefit when added to statin therapy for adults with elevated triglycerides, at a dose of 2 g twice daily. This comes from trials showing that high-dose EPA reduces major adverse cardiovascular events in people with triglycerides ≥150 mg/dL on statins. The effect is thought to come from lowering triglycerides and anti-inflammatory actions that help stabilize plaque, rather than dramatically changing LDL or HDL. It is not a cholesterol absorption inhibitor (that’s ezetimibe), it does not reliably raise HDL-C by a fixed amount, and it does not produce a 50% reduction in LDL-C—LDL changes are not the driver of the observed CV risk reduction.

More practice questions